ASLAN Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
ASLAN Pharmaceuticals's earnings have been declining at an average annual rate of -6.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 53.2% per year.
Key information
-6.4%
Earnings growth rate
18.8%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 53.2% |
Return on equity | n/a |
Net Margin | -368.5% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How ASLAN Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 12 | -44 | 13 | 42 |
30 Sep 23 | 12 | -45 | 13 | 44 |
30 Jun 23 | 12 | -46 | 12 | 44 |
31 Mar 23 | 0 | -58 | 11 | 43 |
31 Dec 22 | 0 | -51 | 10 | 38 |
30 Sep 22 | 0 | -46 | 9 | 36 |
30 Jun 22 | 0 | -45 | 10 | 34 |
31 Mar 22 | 0 | -38 | 11 | 28 |
31 Dec 21 | 0 | -31 | 12 | 22 |
30 Sep 21 | 0 | -28 | 13 | 16 |
30 Jun 21 | 0 | -21 | 11 | 13 |
31 Mar 21 | 0 | -20 | 9 | 11 |
31 Dec 20 | 0 | -16 | 7 | 9 |
30 Sep 20 | 0 | -40 | 7 | 9 |
30 Jun 20 | 0 | -41 | 7 | 11 |
31 Mar 20 | 0 | -47 | 7 | 15 |
31 Dec 19 | 3 | -47 | 9 | 17 |
30 Sep 19 | 3 | -27 | 7 | 22 |
30 Jun 19 | 3 | -34 | 9 | 27 |
31 Mar 19 | 3 | -37 | 10 | 30 |
31 Dec 18 | 0 | -42 | 11 | 32 |
30 Sep 18 | 0 | -45 | 11 | 34 |
30 Jun 18 | 0 | -41 | 11 | 31 |
31 Mar 18 | 0 | -42 | 10 | 31 |
31 Dec 17 | 0 | -41 | 9 | 31 |
30 Sep 17 | 1 | -33 | 9 | 25 |
30 Jun 17 | 12 | -19 | 8 | 22 |
31 Mar 17 | 12 | -14 | 8 | 18 |
31 Dec 16 | 11 | -9 | 7 | 13 |
30 Sep 16 | 11 | -7 | 8 | 8 |
30 Jun 16 | 0 | -15 | 7 | 7 |
31 Mar 16 | 0 | -15 | 7 | 7 |
31 Dec 15 | 0 | -14 | 7 | 6 |
Quality Earnings: ASLN is currently unprofitable.
Growing Profit Margin: ASLN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ASLN is unprofitable, and losses have increased over the past 5 years at a rate of 6.4% per year.
Accelerating Growth: Unable to compare ASLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ASLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: ASLN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.